First National Bank & Trust Co. of Newtown Has $1.21 Million Holdings in Pfizer Inc. (NYSE:PFE)

First National Bank & Trust Co. of Newtown cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 45,652 shares of the biopharmaceutical company’s stock after selling 1,937 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Pfizer were worth $1,211,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Advyzon Investment Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $392,000. Handelsbanken Fonder AB lifted its position in Pfizer by 3.6% during the 4th quarter. Handelsbanken Fonder AB now owns 2,417,446 shares of the biopharmaceutical company’s stock valued at $64,135,000 after purchasing an additional 83,017 shares during the period. Mcdaniel Terry & Co. lifted its position in Pfizer by 7.6% during the 4th quarter. Mcdaniel Terry & Co. now owns 9,316 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 660 shares during the period. Cumberland Partners Ltd acquired a new position in Pfizer during the 4th quarter valued at about $2,032,000. Finally, Ieq Capital LLC lifted its position in Pfizer by 14.3% during the 4th quarter. Ieq Capital LLC now owns 320,472 shares of the biopharmaceutical company’s stock valued at $8,502,000 after purchasing an additional 40,117 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

Shares of PFE opened at $25.87 on Thursday. The stock has a market capitalization of $146.58 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a 50 day moving average of $26.28 and a 200-day moving average of $27.45. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the business earned $0.10 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Ratings Changes

A number of analysts recently weighed in on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.